ADMA Biologics Inc ADMA
9.38
(0.14)
(1.47%)
as of 25 Sep
- Market cap
- $2.1B
- P/E
- 13.0×
Follow ADMA
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
16.85 | 29.90 | 13.06 | 11.63 |
P/S ratio |
7.16 | 8.52 | 4.17 | 3.73 | |
P/FCF ratio |
86.14 | 158.03 | 18.90 | 16.44 | |
P/Operating CF |
263.14 | 121.96 | 36.52 | 64.67 | |
P/B ratio |
8.11 | 9.11 | 5.45 | 4.68 | |
Price to Tangible BV |
8.19 | 9.19 | 5.51 | 4.73 | |
EV/Sales |
7.20 | 8.50 | 4.29 | 3.85 | |
EV/EBITDA |
20.03 | 21.67 | 9.80 | 8.48 | |
EV/Operating CF |
54.13 | 86.04 | 17.07 | 14.44 | |
EV/FCF |
86.61 | 157.64 | 19.46 | 16.99 | |
Quick Ratio |
3.52 | 3.54 | 3.73 | 3.62 | |
Current Ratio |
7.13 | 6.71 | 6.95 | 6.97 | |
Net Debt/EBITDA |
0.34 | (0.18) | 1.03 | 1.16 | |
Debt/Assets |
13.98% | 12.17% | 30.06% | 29.07% | |
Debt/Equity |
0.18 | 0.16 | 0.51 | 0.49 | |
Asset Turnover |
1.02 | 0.92 | 0.87 | 0.82 | |
Operating CF/Net income |
0.36 | 0.72 | 1.29 | 0.78 | |
Capex/Depreciation |
(6.66) | (0.58) | 1.21 | (3.74) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1.14% | 0.99% | 2.27% | 4.83% | |
Selling, General and Administrative Expense of Revenue |
16.22% | 16.89% | 23.36% | 21.49% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
3.76% | 3.87% | 5.53% | 4.93% | |
Graham Net Nets |
0.08 | 0.07 | 0.11 | 0.13 | |
Graham Number |
5.95 | 5.24 | 5.07 | 5.38 | |
Earnings Yield |
5.93% | 3.34% | 7.66% | 8.60% | |
Free Cash Flow Yield |
1.16% | 0.63% | 5.29% | 6.08% | |
Revenue per Share |
0.56 | 0.58 | 0.49 | 0.55 | |
Operating CF per Share |
0.06 | 0.15 | 0.25 | 0.13 | |
Capex per Share |
(0.06) | (0.01) | 0.01 | (0.03) | |
Free Cash Flow per Share |
0.00 | 0.14 | 0.26 | 0.10 | |
Cash per Share |
0.26 | 0.37 | 0.59 | 0.60 | |
Shareholders Equity per Share |
1.81 | 2.00 | 1.65 | 1.79 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.81 | 2.00 | 1.65 | 1.79 | |
Free Cash Flow |
(1.07) | 34.36 | 60.65 | 22.28 | |
Working Capital |
346.17 | 396.97 | 437.63 | 452.45 | |
Capital Expenditures |
(14.37) | (1.28) | 2.40 | (7.26) | |
Net Current Asset Value |
265.15 | 319.59 | 236.31 | 252.20 | |
EV/EBIT |
21.06 | 22.65 | 10.19 | 8.79 | |
Capex to Sales |
0.11 | 0.01 | (0.02) | 0.06 | |
Net Profit Margin |
27.14% | 35.48% | 39.59% | 30.40% | |
Price to Operating Income |
20.94 | 22.70 | 9.90 | 8.51 | |
| Other line items | |||||
Average Receivables |
93.91 | 104.21 | 117.64 | 123.98 | |
Average Payables |
20.02 | 21.37 | 20.57 | 30.75 | |
Average Inventory |
184.23 | 188.35 | 197.14 | 215.39 | |
Average Assets |
479.65 | 556.46 | 587.88 | 621.30 | |
Average Common Equity |
331.54 | 413.17 | 381.87 | 403.27 |
Columns are period end dates